 |
ArchiveAfternoon Spy: Strong Earnings Propel Some Stocks (GMCR, BGS, RGR, CYTX, GNC, IRE, GS, C, CS, MSFT)Posted by Eric Monte at 1:44PM on July 28th
The markets continue to trade higher on Thursday. Investors may be reacting to the initial jobless claims report, which showed claims fell below 400,000 for the first time since April 1. Today’s Top tickerspy Indexes: Coffee Stocks (up 14.5%, see graph): Shares…  Afternoon Spy: Oil Rises As Solar Falls (RENT, DWA, CYTX, BTX, DLLR, FCFS, ORA, HTM, COG, APA, AAPL, LDK, CAT, XOM, SPWRA)Posted by Eric Monte at 2:24PM on June 8th
Markets were searching for direction on Wednesday afternoon, as traders continued to analyze comments made yesterday by Fed Chairman Ben Bernanke about the direction of the economy. In other news, The World Bank revised its 2011 global growth rate from… Morning Spy: Energy Solid, Solar Slumping (CYTX, BTX, RENT, RGC, ORA, NOG, BBEP, COG, PXP, AAPL, SPWRA, LDK, HIHO, XOM, GM)Posted by Eric Monte at 10:48AM on June 8th
Markets were trading flat on Wednesday morning, a day after Fed Chairman Ben Bernanke said the economy is heading in the right direction, just far slower than its potential. The World Bank came out with some disturbing comments as well.… Pluristem Shoots Higher On ‘Buy’ Rating (PSTI, ASTM, BTX, STEM, ATHX, CYTX, GERN)Posted by Todd Shriber at 12:01PM on January 10th
Pluristem Therapeutic (PSTI), the Israel-based bio-therapeutics firm, is up 13% today after National Securities initiated coverage of the maker of cell therapy products with a “buy” rating. National Securities is bullish on Pluristem’s cell delivery and homing capabilities and sees a… Stem Cell Shares Pop On Government Action (GERN, PSTI, STEM, CYTX, STEM, OPXA)Posted by Jason Smith at 12:34PM on September 9th
Recent legal disputes have put the stem cell sector in focus after District Judge Royce Lamberth hit the brakes on an executive order from the Obama administration, which had initially opened the door to federally funded research on human embryonic… Investors Eye Stem Cell Shares Amid Court Dispute (GERN, CYTX, OSIR, OPXA, ASTM, ATHX)Posted by Owen Vater at 9:15AM on August 26th
Earlier this week, U.S. District Judge Royce Lamberth hit the brakes an executive order aimed to remove “barriers to responsible research involving human stem cells,” by ruling that millions in government grants can’t be made. Late in 2009, the Obama… StemCells Spikes On Study Results (STEM, CYTX, GERN, ASTM)Posted by Owen Vater at 10:37AM on August 19th
In a preclinical study, Palo Alto, California-based stem cell research firm StemCells (STEM) demonstrated that its proprietary human neural stem cells can restore motor function in the hind legs of paralyzed mice. According to the company announcement, it is the first… Geron Soars After FDA Lifts Clinical Hold (GERN, ATHX, OSIR, CYTX)Posted by Jason Smith at 3:39PM on July 30th
Geron (GERN) took off by 17% on Friday after the company announced that it will resume testing on its embryonic stem cell-based spinal cord therapy. The firm received notice from the U.S. FDA that a clinical hold on its Phase I… Biotech Shares Pump Up The Volume (ONXX, MNTA, DNDN, ARNA, VVUS, JAZZ, MNKD, CYTX)Posted by Owen Vater at 11:16AM on July 26th
Recently we’ve been directing investors’ attention to volume spikes as a means of identifying the most tradable stocks in volatile equity segments. So often do biotech shares “float” in either direction on relatively sparse news that relative volume is often… Research Community Hails Stem Cell Approval (CUR, CYTX, NBS, OPXA, PSTI, ATHX, KOOL, GERN, OSIR)Posted by Owen Vater at 9:44AM on April 28th
Stem cell stocks were in focus on Wednesday after the National Institutes of Health announced that 13 additional lines of human embryonic stem cells had been cleared for federal funding. Stocks soared on similar news back in December, and according to…  |
|
Follow us on
  |
| Home | Find | Research | Track | Register | My Account | Logout | Web site design by LightMix |
| © 2007-2013 Indie research Corp. All rights reserved. |